SOLX Gold Shunt Cleared in Canada for Surgical Treatment of Glaucoma

August 12, 2009

SOLX has announced that the company has received clearance from Health Canada for the use of the gold shunt in the surgical treatment of glaucoma.

In a prospective, open label study with 12 months of follow-up using SOLX’s GMS+ Gold Shunt, IOP was reduced 45.6% from the Best Medicated Baseline in patients that had failed maximum medical therapy and at least one prior surgical intervention.

The SOLX Gold Shunt is biocompatible, 99.95% pure gold and provides a pathway for the flow of aqueous humor from the anterior chamber of the eye to the suprachoroidal space. This shunt reduces IOP without the formation of a bleb.

Read the release.




Jump down to form below to submit your own comments

Comments are closed.